Vero Biotech logo
  • About Us
  • Products
  • Support
  • News & Events
  • Contact Us
  • Clinician Login

Get in Touch

If you have a comment or question for VERO or would like to schedule a Demo, please provide the following information.

Phone icon

+1 877-337-4118

Map pin icon

387 Nerem Street NW, Suite 125
Atlanta, Georgia 30313

Vero stacked
Does this request relate to a specific patient? (Y/N)*(Required)

Privacy Policy

How would you prefer to be contacted?*(Required)

Contact Info

Map pin icon

387 Nerem Street NW, Suite 125
Atlanta, Georgia 30313

Email icon

contactus@vero-biotech.com

Product Inquiries

To report an adverse event, product questions or complaints, other safety-related information or technical support for a company product

Headphones icon

877-337-4118

Email icon

support@vero-biotech.com

Quick Links

Careers

Prescribing Information

QR code icon

Vita Quick Scan Mobile App

Medical Inquiries

For medical inquiries, click on the Request Form below.

Request Form

Cigna Machine Readable Files
This link leads to the machine-readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of- network allowed amounts between health plans and healthcare providers. The machine readable files are formatted to allow researchers, regulators, and application developers

Vero Biotech logo
ANAB accredited icon

Check our Privacy Policy

Check our Terms of Use

Manage Cookie Settings


Facebook icon
Linkedin icon
Instagram icon

© Copyright 2026 – VERO Biotech. All rights reserved. VERO Biotech and GENOSYL are registered trademarks of VERO Biotech Inc.

Facebook icon
Linkedin icon
Instagram icon

© Copyright 2026 – VERO Biotech. All rights reserved. VERO Biotech and GENOSYL are registered trademarks of VERO Biotech Inc.

Indication & safety
information

Exclamation point in triangle icon

Indication & Safety Information

GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

  • GENOSYL is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
  • Methemoglobin, NO2 and PaO2 should be monitored during nitric oxide administration.
  • In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema. The most common adverse reaction is hypotension.
  • Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
  • Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.
  • See package insert for additional Important Safety Information.

1. Hayu AL, Hanindito E, Hamzah H, Utariani A, Effectiveness of high – flow inhalation anesthesia technique using isoflurane compared to low-flow inhalation anesthesia technique using sevoflurane and isoflurane in terms of cost and safety. Bali J, Anaesthesiol. 2019; 3: 170 – 173. 2. Cotter SM, Petros AJ, Doré CJ, Barber ND, White DC. Low – flow anaesthesia. Anaesthesia. 1991; 46: 1009 – 1012.
 
2. Cotter SM, Petros AJ, Doré CJ, Barber ND, White DC. Low-flow anaesthesia. Anaesthesia. 1991;46:1009-1012.